FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106033433> ?p ?o ?g. }

• W2106033433 endingPage "2026" @default.
• W2106033433 startingPage "2017" @default.
• W2106033433 abstract "(-)-Beta-2',3'-Dideoxy-3'-thiacytidine (lamivudine [3TC]) is a nucleoside analog which effectively interferes with the replication of hepatitis B virus (HBV) DNA in vitro and in vivo. We have investigated the antiviral properties of 3TC in vitro in HepG2 cells infected with recombinant HBV baculovirus. Different types of information can be obtained with the HBV baculovirus-HepG2 system because (i) experiments can be carried out at various levels of HBV replication including levels significantly higher than those that can be obtained from conventional HBV-expressing cell lines, (ii) cultures can be manipulated and/or treated prior to or during the initiation of HBV expression, and (iii) high levels of HBV replication allow the rapid detection of HBV products including covalently closed circular (CCC) HBV DNA from low numbers of HepG2 cells. The treatment of HBV baculovirus-infected HepG2 cells with 3TC resulted in an inhibition of HBV replication, evidenced by reductions in the levels of both extracellular HBV DNA and intracellular replicative intermediates. The effect of 3TC on HBV replication was both dose and time dependent, and the reductions in extracellular HBV DNA that we observed agreed well with the previously reported efficacy of 3TC in vitro. As expected, levels of HBV transcripts and extracellular hepatitis B surface antigen and e antigen were not affected by 3TC. Importantly, the HBV baculovirus-HepG2 system made it possible to observe for the first time that CCC HBV DNA levels are lower in cells treated with 3TC than in control cells. We also observed that the treatment of HepG2 cells prior to HBV baculovirus infection resulted in a slight increase in the efficacy of 3TC compared to treatments starting 24 h postinfection. The treatment of HepG2 cells with the highest concentration of 3TC tested in this study (2 microM) prior to the initiation of HBV replication markedly inhibited the accumulation of CCC DNA, whereas treatment with the same concentration of 3TC at a time when CCC HBV DNA pools were established within the cells was considerably less effective. In addition, our results suggest that in HepG2 cells, non-protein-associated relaxed circular HBV DNA and particularly CCC HBV DNA are considerably more resistant to 3TC treatment than other forms of HBV DNA, including replicative intermediates and extracellular DNA. We conclude from these studies that the HBV baculovirus-HepG2 system has specific advantages for drug studies and can be used to complement other in vitro model systems currently used for testing antiviral compounds." @default.
• W2106033433 created "2016-06-24" @default.
• W2106033433 creator A5021921986 @default.
• W2106033433 creator A5060961843 @default.
• W2106033433 creator A5063684330 @default.
• W2106033433 date "1999-08-01" @default.
• W2106033433 modified "2023-10-17" @default.
• W2106033433 title "Use of the Hepatitis B Virus Recombinant Baculovirus-HepG2 System to Study the Effects of (−)-β-2′,3′-Dideoxy-3′-Thiacytidine on Replication of Hepatitis B Virus and Accumulation of Covalently Closed Circular DNA" @default.
• W2106033433 cites W100585574 @default.
• W2106033433 cites W101585958 @default.
• W2106033433 cites W1496409007 @default.
• W2106033433 cites W1569806478 @default.
• W2106033433 cites W1962682498 @default.
• W2106033433 cites W1984173788 @default.
• W2106033433 cites W2001967406 @default.
• W2106033433 cites W2007423548 @default.
• W2106033433 cites W2007902841 @default.
• W2106033433 cites W2010338556 @default.
• W2106033433 cites W2019018799 @default.
• W2106033433 cites W2026744834 @default.
• W2106033433 cites W2055270948 @default.
• W2106033433 cites W2055399127 @default.
• W2106033433 cites W2059962010 @default.
• W2106033433 cites W2063880330 @default.
• W2106033433 cites W2072585523 @default.
• W2106033433 cites W2073855284 @default.
• W2106033433 cites W2074433769 @default.
• W2106033433 cites W2076171352 @default.
• W2106033433 cites W2077014185 @default.
• W2106033433 cites W2085990351 @default.
• W2106033433 cites W2090886672 @default.
• W2106033433 cites W2096808350 @default.
• W2106033433 cites W2112150016 @default.
• W2106033433 cites W2134812217 @default.
• W2106033433 cites W2139379004 @default.
• W2106033433 cites W2141460271 @default.
• W2106033433 cites W2158381708 @default.
• W2106033433 cites W2164327796 @default.
• W2106033433 cites W2167572870 @default.
• W2106033433 cites W2319441763 @default.
• W2106033433 cites W2323719395 @default.
• W2106033433 cites W4237060995 @default.
• W2106033433 cites W4294216491 @default.
• W2106033433 cites W2091156013 @default.
• W2106033433 doi "https://doi.org/10.1128/aac.43.8.2017" @default.
• W2106033433 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/89407" @default.
• W2106033433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10428929" @default.
• W2106033433 hasPublicationYear "1999" @default.
• W2106033433 type Work @default.
• W2106033433 sameAs 2106033433 @default.
• W2106033433 citedByCount "64" @default.
• W2106033433 countsByYear W21060334332012 @default.
• W2106033433 countsByYear W21060334332013 @default.
• W2106033433 countsByYear W21060334332014 @default.
• W2106033433 countsByYear W21060334332015 @default.
• W2106033433 countsByYear W21060334332016 @default.
• W2106033433 countsByYear W21060334332017 @default.
• W2106033433 countsByYear W21060334332018 @default.
• W2106033433 countsByYear W21060334332019 @default.
• W2106033433 countsByYear W21060334332020 @default.
• W2106033433 countsByYear W21060334332021 @default.
• W2106033433 crossrefType "journal-article" @default.
• W2106033433 hasAuthorship W2106033433A5021921986 @default.
• W2106033433 hasAuthorship W2106033433A5060961843 @default.
• W2106033433 hasAuthorship W2106033433A5063684330 @default.
• W2106033433 hasBestOaLocation W21060334331 @default.
• W2106033433 hasConcept C140704245 @default.
• W2106033433 hasConcept C147483822 @default.
• W2106033433 hasConcept C153911025 @default.
• W2106033433 hasConcept C159047783 @default.
• W2106033433 hasConcept C194575299 @default.
• W2106033433 hasConcept C202751555 @default.
• W2106033433 hasConcept C203014093 @default.
• W2106033433 hasConcept C2522874641 @default.
• W2106033433 hasConcept C2776543447 @default.
• W2106033433 hasConcept C2777333352 @default.
• W2106033433 hasConcept C2777382497 @default.
• W2106033433 hasConcept C2777869810 @default.
• W2106033433 hasConcept C2778600374 @default.
• W2106033433 hasConcept C2780593183 @default.
• W2106033433 hasConcept C2780617729 @default.
• W2106033433 hasConcept C55493867 @default.
• W2106033433 hasConcept C73616013 @default.
• W2106033433 hasConcept C86803240 @default.
• W2106033433 hasConceptScore W2106033433C140704245 @default.
• W2106033433 hasConceptScore W2106033433C147483822 @default.
• W2106033433 hasConceptScore W2106033433C153911025 @default.
• W2106033433 hasConceptScore W2106033433C159047783 @default.
• W2106033433 hasConceptScore W2106033433C194575299 @default.
• W2106033433 hasConceptScore W2106033433C202751555 @default.
• W2106033433 hasConceptScore W2106033433C203014093 @default.
• W2106033433 hasConceptScore W2106033433C2522874641 @default.
• W2106033433 hasConceptScore W2106033433C2776543447 @default.
• W2106033433 hasConceptScore W2106033433C2777333352 @default.
• W2106033433 hasConceptScore W2106033433C2777382497 @default.
• W2106033433 hasConceptScore W2106033433C2777869810 @default.
• W2106033433 hasConceptScore W2106033433C2778600374 @default.
• W2106033433 hasConceptScore W2106033433C2780593183 @default.

• next